LUMO 4.02 Lumos Pharma, Inc.
| Range: | 1.37-4.55 | Vol Avg: | 75884 | Last Div: | 0 | Changes: | 0.24 |
| Beta: | 0.36 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Nov 11 2011 | Empoloyees: | 33 | ||
| CUSIP: | 55028X109 | CIK: | 0001126234 | ISIN: | US55028X1090 | Country: | US |
| CEO: | Mr. Richard J. Hawkins | Website: | https://www.lumos-pharma.com | ||||
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow